BioPharma Resources

Drug Trial Radar · NCT04834024

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

168

Planned (sponsor's estimate)

Start

Jun 2, 2021

Primary completion

Mar 2025

Study completion Mar 2025

Sponsor

Sponsor type
Industry
First posted
Apr 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.

Conditions

  • Follicular Lymphoma and Marginal Zone Lymphoma

Interventions

  • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomideDrug

    The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.

  • lenalinomideDrug

    The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (per IRC)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.